RA Capital Management 13F holdings, Q3 2023
Holdings as of September 30, 2023 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 66 US equity positions worth $5.1bn in its Q3 2023 13F filing. The largest position was ASND at 19.8% of the reported book, followed by LEGN and PCVX. Against the Q2 2023 filing, it opened 8 new positions, added to 9 and reduced 3 among the top 50 holdings.
What did RA Capital Management own in Q3 2023? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2023 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S - ADR | Healthcare | 19.8% | $1.0bn | 10,719,555 | -5% | reduced |
| 2 | LEGN LEGEND BIOTECH CORP-ADR | Healthcare | 8.3% | $420.8m | 6,264,707 | 0% | held |
| 3 | PCVX VAXCYTE INC | Healthcare | 7.9% | $402.3m | 7,891,254 | 0% | held |
| 4 | IMMUNOGEN INC | 4.2% | $211.4m | 13,322,288 | 472% | added | |
| 5 | 89BIO INC | 3.5% | $176.3m | 11,416,948 | 0% | held | |
| 6 | BIIB BIOGEN INC | Healthcare | 2.7% | $137.0m | 532,892 | 0% | held |
| 7 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.6% | $130.1m | 5,676,067 | 0% | held |
| 8 | AEROVATE THERAPEUTICS INC | 2.2% | $112.1m | 8,263,982 | 0% | held | |
| 9 | CYMABAY THERAPEUTICS INC | 2.0% | $103.5m | 6,940,000 | – | new | |
| 10 | VRNA VERONA PHARMA PLC - ADR | 2.0% | $103.0m | 6,317,990 | 0% | held | |
| 11 | TYRA TYRA BIOSCIENCES INC | Healthcare | 2.0% | $99.6m | 7,236,454 | 0% | held |
| 12 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.9% | $98.9m | 17,202,009 | 0% | held |
| 13 | GERN GERON CORP | Healthcare | 1.9% | $97.9m | 46,202,425 | 46% | added |
| 14 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.9% | $95.8m | 7,809,852 | 0% | held | |
| 15 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.8% | $92.4m | 9,165,652 | 6% | added |
| 16 | ANTX AN2 THERAPEUTICS INC | 1.8% | $89.3m | 5,551,295 | 47% | added | |
| 17 | INHIBRX INC | 1.7% | $86.7m | 4,724,207 | 23% | added | |
| 18 | RXST RXSIGHT INC | Healthcare | 1.7% | $85.1m | 3,052,796 | 0% | held |
| 19 | NEWAMSTERDAM PHARMA CO NV | 1.6% | $83.2m | 9,000,000 | 0% | held | |
| 20 | EVH EVOLENT HEALTH INC - A | Healthcare | 1.5% | $74.5m | 2,736,680 | – | new |
| 21 | CUREVAC NV | 1.4% | $72.4m | 10,604,344 | -13% | reduced | |
| 22 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.4% | $69.9m | 1,000,000 | 0% | held |
| 23 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.2% | $62.6m | 6,416,147 | 0% | held |
| 24 | ABOS ACUMEN PHARMACEUTICALS INC | 1.2% | $62.0m | 14,932,063 | 53% | added | |
| 25 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.1% | $58.4m | 18,472,503 | – | new |
| 26 | GHRS GH RESEARCH PLC | 1.1% | $56.2m | 5,587,333 | 0% | held | |
| 27 | ALPINE IMMUNE SCIENCES INC | 1.1% | $53.7m | 4,691,178 | 0% | held | |
| 28 | 4D MOLECULAR THERAPEUTICS IN | 1.0% | $53.0m | 4,163,211 | 36% | added | |
| 29 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.0% | $51.5m | 11,609,704 | 0% | held |
| 30 | ITEOS THERAPEUTICS INC | 1.0% | $48.4m | 4,417,259 | 0% | held | |
| 31 | VOR VOR BIOPHARMA INC | 0.9% | $48.2m | 22,748,880 | 0% | held | |
| 32 | ICOSAVAX INC | 0.9% | $46.2m | 5,963,565 | 0% | held | |
| 33 | ACRV ACRIVON THERAPEUTICS INC | 0.9% | $46.0m | 4,810,508 | 0% | held | |
| 34 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.8% | $42.1m | 1,977,901 | – | new |
| 35 | PEPG PEPGEN INC | Healthcare | 0.8% | $41.3m | 8,131,952 | 0% | held |
| 36 | AVIDITY BIOSCIENCES INC | 0.8% | $40.9m | 6,416,998 | 0% | held | |
| 37 | CTKB CYTEK BIOSCIENCES INC | Healthcare | 0.7% | $37.6m | 6,809,404 | -45% | reduced |
| 38 | SOLENO THERAPEUTICS INC | 0.7% | $36.6m | 1,239,000 | – | new | |
| 39 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.7% | $35.8m | 9,459,678 | 214% | added |
| 40 | CLYM ELIEM THERAPEUTICS INC | 0.7% | $34.6m | 13,150,849 | 0% | held | |
| 41 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.6% | $30.8m | 2,007,946 | 0% | held |
| 42 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 0.6% | $30.6m | 1,762,000 | 0% | held |
| 43 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.6% | $30.2m | 3,178,476 | 0% | held |
| 44 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 0.6% | $30.1m | 4,398,453 | 0% | held |
| 45 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 0.6% | $29.9m | 204,500 | – | new |
| 46 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.6% | $29.0m | 2,122,465 | 0% | held |
| 47 | EYPT EYEPOINT PHARMACEUTICALS INC | Healthcare | 0.5% | $26.9m | 3,370,506 | 0% | held |
| 48 | URGN UROGEN PHARMA LTD | Healthcare | 0.4% | $20.8m | 1,483,697 | – | new |
| 49 | TNYA TENAYA THERAPEUTICS INC | 0.3% | $17.1m | 6,718,483 | 11% | added | |
| 50 | BCYC BICYCLE THERAPEUTICS PLC-ADR | Healthcare | 0.3% | $16.1m | 800,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.